NSAAs are used in clinical medicine for the following indications: * Prostate cancer in men * Androgen-dependent skin and hair conditions like acne, hirsutism, seborrhea, and pattern hair loss (androgenic alopecia) in women * Hyperandrogenism, such as due to polycystic ovary syndrome or congenital adrenal hyperplasia, in women * As a component of hormone therapy for transgender women * Precocious puberty in boys * Priapism in men Available forms s marketed for clinical or veterinary use Generic name Class Type Brand name(s) Route(s) Launch Status a Nonsteroidal Androgen synthesis inhibitor Cytadren, Orimeten Oral 1960 Availableb 222,000 Nonsteroidal AR antagonist Erleada Oral 2018 Available 50,400 Nonsteroidal AR antagonist Casodex Oral 1995 Available 754,000 Nonsteroidal AR antagonist Xtandi Oral 2012 Available 328,000 Nonsteroidal AR antagonist Eulexin Oral 1983 Available 712,000 Nonsteroidal Androgen synthesis inhibitor and weak AR antagonist Nizoral, others Oral, topical 1981 Available 3,650,000 Nonsteroidal AR antagonist Anandron, Nilandron Oral 1987 Available 132,000 Nonsteroidal AR antagonist Eucapil Topical 2003 Availableb 36,300 Footnotes: a = Hits = Google Search hits (as of February 2018). b = Availability limited / mostly discontinued. Class: Steroidal = . Nonsteroidal = . Sources: See individual articles.
Nonsteroidal antiandrogen
Antiandrogen
Steroidal antiandrogen
Nonsteroidal estrogen
Antiprogestogen
Antiestrogen
N-Terminal domain antiandrogen
Thyroid blocker